On June 6, 2022 TriSalus Life Sciences, an interventional immunotherapy company on a mission to extend and improve the lives of patients with liver and pancreatic tumors, reported that it will present a series of events at the Society of Interventional Radiology (SIR) 2022 Annual Scientific Meeting, held June 11-16, 2022, at the Boston Convention and Exhibition Center (Press release, TriSalus Life Sciences, JUN 6, 2022, View Source [SID1234615767]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The TriSalus clinical leadership team will be on-site to discuss the company’s FDA-cleared TriNav Infusion System as well as ongoing research with the interventional radiology (IR) community, including two presentations on new pre-clinical data that inform the company’s immunotherapeutic platform approach.
The company is pioneering an integrated platform approach that aims to overcome immunosuppression and delivery barriers by combining an investigational toll-like receptor 9 agonist, SD-101, with innovative drug delivery technology. The TriNav Infusion System utilizes the Pressure-Enabled Drug Delivery (PEDD) method of administration with SmartValve to overcome intratumoral pressure and improve delivery of therapeutic agents during outpatient interventional radiology procedures.
Additional activities, including a Monday evening reception, are highlighted below.
ON-SITE TRISALUS SPOKESPERSONS
Steven C. Katz, MD, FACS, Chief Medical Officer
David B. Jaroch, PhD, Senior Principal Scientist
Alexander Y. Kim, MD, Director of Interventional Oncology Clinical Strategies
Mikael Trollsas, PhD, Senior Vice President of Research and Development
CONFERENCE ACTIVITIES
Sunday, June 12 – Tuesday, June 14
TriNav Exhibition, Booth #605
Visit Booth #605 to see a replica of the TriNav Infusion System and learn how the device is engineered to improve tumor response, increase therapeutic delivery, and target tumors more precisely.
Sunday, June 12
Hands-on Workshop, Interventional Oncology: Embolization, 3:00 – 4:30pm ET, Exhibit Hall C
During this interactive workshop, attendees can experience what makes the TriNav Infusion System different from standard delivery approaches.
Monday, June 13
Taste of New England: An Evening Reception, Presented by TriSalus Life Sciences, 6:30-8:00pm ET
Westin Boston Seaport – Marina Ballroom II
Join the TriSalus team for an evening networking and education reception, complete with New England favorites. (Media RSVP for the event by emailing [email protected].)
Wednesday, June 15
(Scientific Sessions listed below are part of the SIR 2022 CME-accredited scientific program and not a TriSalus-sponsored activity.)
Scientific Session: IO Frontiers 2, 3:18-3:27pm ET, Room 253B
Abstract Title: Improved Delivery of a TLR-9 Agonist to Liver Tissue by Intravascular Pressure Enabled Drug Delivery (PEDD) Compared with Direct Needle Injection
Hear TriSalus Senior Principal Scientist David B. Jaroch, PhD highlight promising results from a pre-clinical study comparing local injection of labeled SD-101 into hepatic tissue versus using the PEDD method.
Scientific Session: Venous Disease and Sampling, 4:21-4:30pm ET, Room 258A
Abstract Title: Comparison of Pancreatic Tissue Uptake of Oxaliplatin Delivered by Systemic Circulation and by Pancreatic Retrograde Venous Infusion (PRVI)
TriSalus Senior Principal Scientist David B. Jaroch, PhD will present on the development of a trans-venous approach for regional treatment of pancreatic tumors, using a catheter capable of modulating pressure and flow within the organ to promote drug uptake.